Biochemical disease‐free survival in patients with a high prostate‐specific antigen level (20–100 ng/mL) and clinically localized prostate cancer after radical prostatectomy

Abstract

Patients with a high serum PSA level (20-100 ng/mL) may be appropriate candidates for RP. While the cancer-free survival is not as good as in patients with a lower PSA, a significant percentage of patients achieve BDFS. No preoperative variables were predictive of disease-free survival or time to PSA recurrence.